CFO Tribune

CFO appointment

Quince Therapeutics, Inc. appoints John Militello as CFO

Quince Therapeutics, Inc. reported in a Form 8-K filed July 31, 2026 that John Militello was appointed Chief Financial Officer.

In the filing's words

John Militello, CPA , age 52, was conditionally appointed as the Company’s Chief Financial Officer and will serve as the Company’s Principal Financial Officer and Principal Accounting Officer upon his appointment.

Verbatim from sec.gov, Item 5.02. We quote departures; we do not characterize them.

CompanyQuince Therapeutics, Inc. (QNCX)
EventAppointment
IncomingJohn Militello
Title in the filingChief Financial Officer
Effectivenot stated in the source
8-K filedJuly 31, 2026
Internal promotionYes
Prior role (per filing)Head of Finance, Orphai Therapeutics, LLC
SEC CIK0001662774

Quince Therapeutics, Inc. reported this change in a Form 8-K, Item 5.02, filed July 31, 2026. The filing's own words are quoted above.

Sources

  • sec.gov · SEC filing, Item 5.02 · accessed 2026-09-26

Documented unknowns

  • effective: The filing gives "the Effective Time", which is not a calendar date.

Something wrong about John Militello? Send a correction with the primary source.